NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board
Vancouver, British Columbia (Newsfile Corp. - January 26, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer s Disease Scientific Advisory Board ( AD-SAB ) with the appointment of four world-class scientists and clinical researchers in Alzheimer s disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies.
Share or Print this page
In aggressive pursuit of its vision of a world without Alzheimer’s and all other dementia, the Association once again made its
largest-ever research investment in FY20,
granting more than $47 million to 139 new scientific investigations. Investments included awards to 119 projects funded through the
International Research Grant Program, representing proposals ranked highest by a peer-reviewed process in a highly competitive field of 406 applications submitted from 865 letters of intent. As the world’s leading nonprofit funder of Alzheimer’s and dementia research, the Association is currently investing $208 million in more than 590 active best-of-field projects in 31 countries.
The Association paused funding programs in March 2020 after hearing significant challenges from potential applicants in submitting their necessary documents for consideration as a result of the COVID-19 pandemic. The Association continues to be in touch with multi